Roche AIDS drug development
Executive Summary
Hoffmann-La Roche seeking to out-license one of three AIDS drugs under development, the TAT-inhibitor RO 24-7429. In-progress Phase I trials, which were halted in April following the decision to license the drug, will continue under Roche until a partner is found, the company said. Roche will focus research efforts on its two other AIDS drugs, ddC (Hivid) ("The Pink Sheet" March 18, T&G- 6), for which the company is filing an NDA, and a protease inhibitor.